ALKERMES | ALKS - Ebitda

Stock Price
27.76
Daily Change
0.12 0.43%
Monthly
-15.62%
Yearly
-18.42%
Q1 Forecast
26.93

ALKERMES reported $100.31M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
ALKERMES USD 100.31M 21.24M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Coherus Biosciences USD -44.34M 9.82M Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
J&J USD 9.52B 389M Sep/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Otsuka Holdings JPY 99.77B 94.02B Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025